Advancement in treatment options for your cervical cancer patients: Final analysis data of KEYNOTE-826

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

PDF, 803 KB

The Advancement in treatment options for your cervical cancer patients: Final analysis data of KEYNOTE-826 infographic summarises the eligible patient for treatment with KEYTRUDA® (pembrolizumab) in combination with chemotherapy with or without bevacizumab for patients with persistent, recurrent or metastatic CPS >1 cervical cancer and the key outcomes from the KEYNOTE-826 Final analysis.

More information about KEYTRUDA® (pembrolizumab) in cervical cancer

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website